Terminated PHASE2 INTERVENTIONAL NCT00159640

Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia

A Multi-Center, Randomized, Double Blind, Dose-Response, Placebo And Gabapentin Controlled Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia

Sponsor: Pfizer

Conditions Pain

Interventions PD-217,014

Updated 6 times since 2017 Last updated: Mar 27, 2007 Started: Feb 29, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Pfizer

See all terminations from Pfizer

Other Pain trials with similar outcome

Browse all Pain trials

A PHASE2 clinical study on Pain, this trial is terminated or withdrawn. The trial is conducted by Pfizer and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arnhem, Netherlands , Barcelona, Spain , Bedford Park, Australia , Breda, Netherlands , Brno, Czechia , CZ-Praha 8, Czechia , Granada, Spain , Halifax, Canada , Kampen, Netherlands , Kelowna, Canada and 21 more locations